Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8813040 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL30909503 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL30052986 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL3030885 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL3031777 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL28390578 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL8811513 | 1.00 | LMNA (0.39) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL3041307 | 0.98 | LMNA (0.40) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| Benzene SCHEMBL28158350 | 0.94 | RARB (0.38) | LMNAHIF1AEPAS1RARBALDH1A1 | |
| SCHEMBL16174549 | 0.92 | LMNA (0.54) | LMNAHIF1AEPAS1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116573981-B | Resolution method of beta receptor blocker raceme medicine | 中南大学 | 2025-05-06 | — | — | CN | claimed |
| CN-114409510-B | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116573981-A | Resolution method of beta receptor blocker raceme medicine | 中南大学 | 2023-08-11 | — | — | CN | claimed |
| CN-116375550-A | Method for resolving racemate compound by enantioselective reverse micelle extraction | 中南大学 | 2023-07-04 | — | — | CN | claimed |
| CN-114409510-A | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-116573981-B | Resolution method of beta receptor blocker raceme medicine | 中南大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-114409510-B | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-114409510-B | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-114409510-B | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111090826-B | Optimizing device, method implemented by optimizing device, and computer-readable storage medium | 富士通株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116573981-A | Resolution method of beta receptor blocker raceme medicine | 中南大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-111310930-B | Optimizing apparatus, optimizing method, and non-transitory computer-readable storage medium | 富士通株式会社 | 2023-07-21 | — | — | CN | disclosed |
| CN-114409510-A | Method for promoting hydrolysis of isooctyl isooctanoate and isooctyl formate | 大连普莱瑞迪化学有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4795807-A | Preparation of azo dyestuffs by diazotization and coupling in the presence of an ester | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | LMNA 1804/4885HIF1A 1355/4885EPAS1 4545/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | LMNA 1804/4885HIF1A 1355/4885EPAS1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.